Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Health

Study looks at the use of TEMPOL as a potential treatment for COVID-19

Staff Writer
Staff Writer 12 months ago
Updated 2021/10/23 at 1:49 PM
Share
SHARE

Researchers with the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development have revealed a potential new promising experimental drug for COVID-19. The study was released in Science.

Named TEMPOL, researchers focused on an enzyme called RNA replicase.

“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19), uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes,” according to researchers.

“We found that the catalytic subunit of the RdRp, nsp12, ligates two iron-sulfur metal cofactors in sites that were modeled as zinc centers in the available cryo-electron microscopy structures of the RdRp complex.”

“These metal binding sites are essential for replication and for interaction with the viral helicase. Oxidation of the clusters by the stable nitroxide TEMPOL caused their disassembly, potently inhibited the RdRp, and blocked SARS-CoV-2 replication in cell culture. These iron-sulfur clusters thus serve as cofactors for the SARS-CoV-2 RdRp and are targets for therapy of COVID-19,” researchers also found.

In spite of the findings, clinical studies are necessary to establish the drug’s potential effectiveness in patients.

“Given TEMPOL’s safety profile and the dosage considered therapeutic in our study, we are hopeful. However, clinical studies are needed to determine if the drug is effective in patients, particularly early in the disease course when the virus begins to replicate,” said one author of the study in a press release.

Photo: AP

You Might Also Like

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

New research of vegetarian diets uncovered similar growth and nutrition as meat consumers

Being overweight during childhood may raise the risk of type 1 diabetes

Over a million less smokers projected after U.S. ban on menthol cigarettes: study

Study probes the communication between physicians and patients regarding e-cigarette use

TAGGED: COVID-19, epidemiology, TEMPOL
Staff Writer June 3, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article The majority of Americans favor the death penalty, survey finds
Next Article Middle Eastern people more likely to be victims of racial bias: British study

Recommended

Clinical

New research claims COVID-19 contagion may raise the risk of neurodegenerative disorder

1 Min Read
Health

New research of vegetarian diets uncovered similar growth and nutrition as meat consumers

1 Min Read
Health

Being overweight during childhood may raise the risk of type 1 diabetes

1 Min Read
Health

Over a million less smokers projected after U.S. ban on menthol cigarettes: study

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?